Omeros (NASDAQ:OMER) Azioni, Quote.MetaTitle.unusual-options

Omeros

Omeros Corp

Aurora Cannabis

Aclaris Therapeutics, Inc. - Common Stock

Aclaris Therapeutics

Alumis

Alto Neuroscience

Aquestive Therapeutics, Inc. - Common Stock

Aquestive Therapeutics

Arvinas

Atea Pharmaceuticals, Inc. - common stock

Atea Pharmaceuticals

Bioage Labs

Canopy Growth Corporation - Common Shares

Canopy Growth

Contineum Therapeutics, Inc. - Common stock

Contineum Therapeutics

Cybin

Evolus

Esperion Therapeutics, Inc. - Common Stock

Esperion Therapeutics

Eton Pharmaceuticals, Inc. - Common Stock

Eton Pharmaceuticals

Fulcrum Therapeutics, Inc. - Common Stock

Fulcrum Therapeutics

High Tide

LB Pharmaceuticals

LENZ Therapeutics

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals

MediWound

Neumora Therapeutics, Inc. - Common Stock

Neumora Therapeutics

SIGA Technologies

SNDL

Ventyx Biosciences

Zevra Therapeutics

Omeros (OMER) Previsione

Notizie

Utili

Quote.Nav.option-chain

Guidance

Valutazioni degli analisti

Insider trading

Vendite allo scoperto

Rapporto azionario

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Comments

Omeros Opzioni Inusuali

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO